Volume 1, Issue 1 (2020)

1. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. 2020. 

2. Amin, M. P-glycoprotein Inhibition for Optimal Drug Delivery. Drug Target Insights. 2013;7:p.DTI.S12519. 

3. Barretto, N. et al. (2005) “The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Actiity”, Journal of Virology, 79(24), pp. 15189-15198. doi: 10.1128/ jvi.79.24.15189-15198.2005. 

4. Benet L.BDDCS, the Rule of 5 and drugability. Advanced Drug Delivery Reviews. 2016;101:89-98. 

5. Chuck C. Profiling of Substrate Specificities of 3C-Like Proteases from Group 1, 2a, 2b, and 3 Coronaviruses. PLoS ONE. 2011;6(11):e27228. 

6. DeLano WL. PyMOL. DeLano Scientific, San Carlos, CA, 700 Electrophoresis. 2002;18:2714-2723. 

7. Feixiong Cheng, Weihua Li, Yadi Zhou, Jie Shen, Zengrui Wu, Guixia Liu, Philip W. Lee, Yun Tang. admetSAR: A comprehensive sourceand free tool for evaluating chemical ADMET properties. J. Chem. Inf. Model. 2012;52(11):3099-3105. 8. Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, Poroikov VV, et al. Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. Chemistry of Heterocyclic Compounds. 2014;50(3):444- 457. doi: 10.1007/s10593-014-1496-1. 9. Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, Poroikov VV, et al. Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. Chemistry of Heterocyclic Compounds. 2014;50(3):444- 457. doi: 10.1007/s10593-014-1496-1